Topline results from a phase 1 extension study show EO2002, a nonsurgical cell therapy for corneal edema, improved best corrected visual acuity at 6 months and maintained a strong safety profile, according to a press release from Emmecell.
“These findings strongly support advancing EO2002 into phase 3 trials, bringing us closer to providing a transformative, nonsurgical treatment for patients with corneal edema,” Jeffrey L. Goldberg, MD, PhD, the company’s co-founder and professor and chair of ophthalmology at Stanford University, said in the release.
In the multicenter,